circulating B cells as determined by immunofluorescence. Of the circulating lymphocytes, 41% had a-immunoglobulin heavy chains, 3% y chains, and 3% p chains. Synthesis of y heavy chain classes showing wide heterogeneity and cu and p chains of restricted mobility was demonstrated by radioimmunoelectrophoresis. Because of the patient's poor clinical response to exogenous y-globulin administration and the paradoxic presence of circulating B cells, with the capacity to synthesize immunoglobulins in vitro, we elected to begin a course of therapy with transfer factor. After the initial four doses of transfer factor ( 2 x lo8 lymphocytes/dose) his serum IgG rose from 50 to 130 mg/100 ml, the same level which he had previously attained during continuous exogenous y-globulin therapy. His serum IgG has remained at this level for the past 12 months with trimonthly booster doses of transfer factor. The patient has not required any additional y-globulin therapy and he has remained clinically asymptomatic.
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Speculation
Our studies in a patient with agammaglobulinemia have shown that transfer factor therapy may affect immunoglobulin synthesis. The concurrent discontinuation of exogenous y-globulin administration makes it difficult to attribute the changes to only one or another aspect of therapy. We await further reports of the effects of transfer factor in the therapy of patients with B cell disorders.
Congenital agammaglobulinemia has been considered a stem cell deficiency involving thymic-independent B lymphocytes with sparing of thymic-dependent T lymphocytes. The paradoxic finding of B lymphocytes with surface immunoglobulins and receptors for complement in the peripheral circulation of some patients with agammaglobulinemia (16, 19) , however, argues against a stem cell origin for this disorder. Extensive investigations in the mouse confirm that T lymphocytes are instrumental in the facilitation and suppression of immunoglobulin and antibody production by B lymphocytes (13) . Recent studies in man have further demonstrated a variable T lymphocyte deficiency in some patients with the clinical and laboratory manifestations of congenital agammaglobulinemia (21) . These findings suggest that the B cell dysfunc-tion that occurs in some patients with agammaglobulinemia may result from faulty T-B cell interaction.
Transfer factor, a dialyzable extract of peripheral blood leukocytes, has been shown to transfer to the recipient the specific cell-mediated immune responses of the donor (14) . Transfer factor administration in the Wiskott-Aldrich syndrom'e has resulted in a general improvement in the condition of these patients (23, 24) , suggesting that transfer factor may nonspecifically augment immune responses as well. Although the effects of transfer factor on T-B cell interaction have not been defined, such an effect could explain these "nonspecific" findings. Our experience with the use of transfer factor to alter the clinical course of a patient with agammaglobulinemia suggests that transfer factor may have the potential to influence T-B cell interaction.
CASE HISTORY JF, a 9-year-old male foster child, the 9-lb, 3-oz product of a reportedly normal pregnancy and delivery, has had a long standing history of frequent infections with hospitalizations beginning in his perinatal period. H e spent the first 6 months of his life in an isolation ward because of recurrent sepsis and pneumonia. His repeated infections have included otitis media (which led to bilateral deafness by 3 years of age), pneumonia, impetigo, and bacterial meningitis. At the age of 3 years the diagnosis of agammaglobulinemia was made and he was subsequently treated with biweekly doses of 0.6 ml/kg commercial -y-globulin until he was 8 years old. In spite of this therapy the frequency and severity of his infections did not abate and he was referred to the Department of Pediatrics, Division of Infectious Diseases of the Mount Sinai School of Medicine for further evaluation and treatment.
He was initially seen on January 24, 1973 and was found to be well developed with a height of 52 inches (50th percentile) and weight of 70 Ib (50th percentile), with abnormally shaped ears, a barrel chest, and bilateral rales. Hyperkinetic behavior and a speech defect were noted. These had led previously to numerous neurologic evaluations, all of which were considered normal. His peculiar behavior has since been attributed to his early unrecognized deafness. N o lymph nodes were palpable. The tonsils were absent, having been surgically removed in early childhood (the tissue was not studied at that time and is not available). The spleen and liver were not enlarged.
Initial blood studies revealed a hemoglobin of 13.1 mg/100 ml and a white blood count of 16,100/mm3 with 44% segmented polymorphonuclear cells, 21% bands, 23% lymphocytes, 9% monocytes, and 3% eosinophils. The chest x-ray was normal without evidence of chronic disease. N o thymic shadow could be seen. An extensive work-up of T and B cell function was undertaken as described under Methods. Results appear in Tables 1, 2 , and 3. In general he was found to have low levels of IgG and absent IgA. Low levels of IgM were present. A small percentage of B cells were detected by rosetting and by immunofluorescent techniques.
Because of his poor clinical response to exogenous IgG administration and the paradoxical presence of circulating B cells, we elected to begin a course of therapy with transfer factor. Three biweekly doses of transfer factor (2 x lo8 lymphocytes/dose) were administered, followed by trimonthly booster doses. Since the onset of transfer factor therapy, the patient has been maintained essentially free of infections and is without symptomatic complaints of any kind.
METHODS S K I N TESTS
Cutaneous reactivity to a variety of skin test reagents were studied, including (1) Candida albicans extract (CAg, allergenic extract (29)) used in dilutions of 1: 1000 and 1: 100 in sterile saline; (2) streptokinase-streptodornase (Varidase (30)). used a t doses of 10-2.5 units and 40-10 units diluted in sterile saline; and (3) Trichophyton extract (Trich, allergenic extract (29) ). used in dilutions of 1:1000 and 1:100 in sterile saline. These skin test reagents were injected intradermally in the volar aspect of the patient's forearm in volumes of 0.1 ml. The largest diameter of the indurated area was measured in millimeters with calipers at 24 and 48 hr. Any induration was considered a positive response. Erythema was not used as an indication of a positive reaction.
T CELL ROSETTES T cell rosettes were assayed by the method of Wybran et al. (28) . Lymphocytes, isolated on a Ficoll-Hypaque gradient (3), were placed in plastic tubes containing 0.05 ml heat-inactivated fetal calf serum which had been absorbed previously with sheep red blood cells (RBC). 0.2 ml of sheep RBC (8 x lo6) were added with a final ratio of sheep RBC to lymphocytes of 8: 1. The tubes were spun for 5 min at 800 rpm and then were left undisturbed at room temperature for 60 min. The cell pellets were then resuspended by gentle shaking and two lots of 500 lymphocytes were counted on a standard hemocytometer. A rosette-forming cell (RFC) was considered to be a lymphocyte with at least three adherent sheep RBC. The results are expressed as the percentage of R F C per total number of lymphocytes present. Normal values for our lab are 45-55%.
IN VITRO PHYTOHEMAGGLUTIN (PHA) REACTIVITY
Lymphocyte reactivity to'PHA in vitro was studied according to the method of Waithe and Hirschhorn (27) using 4 pg/ml of MR68 P H A (31) . D N A synthesis was measured at 72 hr as the amount of incorporation of [14C]thymidine (32) (uniformly labeled with specific activity 53.8 mCi/mmol) as determined with a Packard Tri-Carb liquid scintillation spectrophotometer model 3375.
S E R U M IMMUNOGLOBULINS A N D ANTIBODY STUDIES
Serum immunoglobulins were determined by the Mancini radial immunodiffusion method (20) . In our laboratory the range of normal values for patients above 4 years of age is IgG 500-1,500 mg/ 100 ml, IgA 60-460 mg/ 100 ml, and IgM 30-130 mg/ 100 ml.
Isohemagglutinins were kindly assayed by the Mount Sinai Hospital Blood Bank.
Diphtheria antibody titers and tetanus antibody titers were performed at the Center for Disease Control, Atlanta, Ga., by the method of Schubert and Cornell (22) . The results are expressed in hemagglutinating units (a.u.); 0.01 a.u. is considered a protective titer.
Neutralizing antibody to diptheria toxin was determined by injecting 0.1 ml of active Schick toxin (33) intracutaneously in the volar aspect of the patinet's forearm (Schick test). The reaction was considered positive, indicative of the absence of neutralizing antibody of IgG class (4) if erythema was present at the site of injection after 5 days. T o control for delayed hypersensitive reaction to the product, 0.1 ml diphtheria toxoid (prepared by heating Schick toxin to 85' for 30 min) was injected into the volar aspect of the opposite forearm of the patient. Induration at 48 hr at the control site distinguishes an immune response from a toxic, erythematous response to Schick toxin, which would appear in the nonimmune individual at 5 days on the opposite forearm.
B CELL ROSETTES B cell rosettes were tested according to the method of Lay et al. (17) . Sheep RBC (0.25 ml) sensitized with rabbit anti-sheep amboceptor and complement (EAC) was mixed with 0.25 ml containing lo6 lymphocytes. The cells were incubated at 37' for 30 min with slow agitation provided by a rotary rack. Two hundred lymphocytes were then counted on a standard hemocytometer. An R F C was considered to be a lymphocyte with at least three adherent sheep RBC. The results are expressed as the percentage of R F C per total number of lymphocytes present. Normal values for our laboratory are 10-17%. IMMUNOFLUORESCENT STAINING serially quick frozen in acetone-Dry Ice followed by thawing in a Lymphocyte reactivity to pokeweed mitogen was studied according to the method of Waithe and Hirschhorn (27) using a I: 100 dilution of pokeweed mitogen (34) diluted in R P M I 1640 (35) containing 100 pg/mi of streptomycin, 100 p/ml penicillin, 29.2 mg/ml L-glutamine, and 20% heat-inactivated fetal bovine serum. D N A synthesis was measured at 120 hr as the amount of incorporation of [14C]thymidine (32) (uniformly labeled with specific activity 53.8 mCi/mmol) using a Packard Tri-Carb liquid scintillation spectrophotometer model 3375. Radioimmunoelectrophoresis was performed according to the method of Chessin et a/. (6) .
In Vitro Production of 14C-Labeled Proteins. Synthesis of immunoglobulins by stimulated peripheral blood lymphocytes was demonstrated with radioimmunoelectroohoretic techniaues following the incorporation of 14C-amino acids into newly synthesized protein. A standard labeling medium was employed for this procedure consisting of Eagle's Spinner minimal essential medium-deficient in L-leucine and supplemented with L-[14C]leucine (specific activity 280 mCi/mM (32)), 10% heat-inactivated fetal calf serum, and fresh L-glutamine. The final concentration for the radioactive amino acid was 1 pCi/ml. Lymphocytes stimulated by pokeweed mitogen as previously described were harvested at 72 hr by centrifugation at 800 rpm for 20 min. For biosynthesis, 0.2-ml aliquots of washed cells (approximately 1 x lo7) were added to 1.8 ml labeling medium in screw disposable glass culture tubes, 16 x 125 mm. After incubation for 18 hr at 37" in an upright stationary position, the cultures were frozen, thawed, and centrifuged at 15,000 x g for 20 min. The supernatants were then dialyzed against 100 volumes of 0.014 M NaCl for 48 hr at 4" to remove unincorporated amino acid. The dialysate was lyophilized and reconstituted to 1/10 the original volume with distilled water.
Radioimmunoelectrophoresis. Microimmunoelectrophoresis was performed in 1.5% agar with barbital acetate buffer, p 0.05, p H 8.6 at 5 V/cm for 60 min. Precipitin arcs obtained by coprecipitation with human serum (12) were developed for 48 hr with rabbit anti-human polyvalent and rabbit anti-human antisera specific for human immunoglobulin heavy chain, classes, a, y, and p. Radioautography was performed by exposing Kodak medical, no screen, x-ray film to the dried plates for 6 weeks. After the autoradiographs were developed the immunoelectrophoretic pattern was stained with fast green and the radioautographs were compared with the stained plates to determine electrophoretic mobilities of the labeled precipitin areas.
TRANSFER FACTOR PREPARATION
Transfer factor was prepared according to the method of Lawrence (15) . Heparinized blood (400 ml) was obtained from healthy donors who demonstrated a strongly positive cutaneous reactivity to 1:1000 CAg or Trichophyton. Lymphocytes, 3-4 x lo8, obtained from the leukocyte-rich plasma supernatant of the sedimented blood, were resuspended in 9 ml sterile saline in Pyrex glass tubes. T o this suspension of cells 1 mg sterile DNase (36) was added with 0.5 ml of 10% magnesium sulfate. The tubes were then 37" water bath for a total of seven cycles. The extract wa; then dialyzed against 100 ml sterile distilled water for 24 hr at 4'. In these studies one unit of transfer factor is equivalent to 1 x lo8 lymphocytes. Before use the lyophilized transfer factor was reconstituted in 2 ml sterile distilled water, sterilized by 0.45-mp Millipore filtration and then was immediately injected intramuscularly. (TABLE I) Our patient appeared to have grossly intact T cell responses. He was noted to have a mildly positive skin reactivity to Candida antigen and Trichophyton with induration at 1: 100 dilution but not at 1: 1000 dilution. N o response to streptokinase-streptodornase was noted, although in our larger experience 75% of children 8 years of age tested respond to streptokinase-streptodornase. A normal percentage of circulating direct sheep RBC rosetting cells (T cells) was detected (60%). A control sample from a normal individual done at the same time showed 55% T cell rosettes.
RESULTS T CELL RESPONSES
The in vitro P H A response of our patient was comparable with that of the control with a rise from a baseline of 196 cpm to 17,700 cpm by the patient's stimulated cells. This 90-fold increment is similar to the I I l-fold increment above background count demonstrated by the stimulated cells of the control.
B CELL RESPONSES (TABLE 2)
The patient was found to be blood group 0. Isohemagglutinins against blood group substance A were 1: 1. Diphtheria antitoxin antibodies were present in a protective titer of 0.038 a.u. N o antibodies to SalmoneNa typhi groups 0 , H , B, C,, C2, D, and E were detected. Latex fixation for rheumatoid factor was negative. In spite of the presence of protective titers of diphtheria antibody in the serum, the patient's Schick test was positive. Circulating B cells as determined by EAC rosetting were present although in small numbers (4.6% for the patient and 13% for the control). A small number of circulating cells could be shown by immunofluorescent techniques to bear surface immunoglobulins. Of these, 4% had a heavy chains, 3% y chains and 3% p chains. Our patient responded to pokeweek mitogen with an increase from 29-760 cpm. His 25-fold increment in incorporation of ['"]thymidine with pokeweejc mitogen stimulation is comparable with the 28-fold increment demonstrated by the control.
By radioimmunoelectrophoresis it was shown that the patient's pokeweed mitogen-stimulated lymphocytes have the capacity to synthesize a , y, and p chain classes of immunoglobulins (Fig. 1) . The y heavy chains show wide heterogeneity. Only a and p chains of restricted mobility were produced.
RESPONSES TO TRANSFER FACTOR THERAPY (TABLE 3)
Unfortunately, our transfer factor donor was not streptokinasestreptodornase positive. Since our patient had a positive skin response to both Candida antigen and Trichophyton before transfer factor therapy we were unable to test the effectiveness of our transfer factor by the acquisition by our patient of new skin test reactivities. Furthermore, no increase in the existing reactivities of our patient were noted after transfer factor. The patient remained positive to both Candida antigen and Trichophyton at 1:100 dilution, but did not respond to the 1:1000 dilution. Our donor was positive to 1: 1000 dilutions of both skin test antigens. We ordinarily require the transfer of some cutaneous reactivity to control for the viability of the transfer factor used. That this transfer factor was active is demonstrated by its effect in an additional patient. A portion of this same transfer factor was found to increase the circulating T cell rosettes of a patient with thymic dysplasia from 5% to 40% (5).
The patient's immunoglobulins were measured 14, 50, 70, 168, and 270 days after the discontinuation of exogenous IgG therapy (both pre-and post-transfer factor therapy). Before transfer factor ' Mean of triplicate cultures. therapy (14 days after his last exogenous IgG), the patient had an IgG of 140 mg/100 ml and an IgM of 35 mg/100 ml. Fifty days after his last exogenous IgG (also pretransfer factor therapy) the patient's IgG was 70 mg/100 ml, and the IgM was 10 mg/100 ml. After two doses of transfer factor (70 days after the last dose of exogenous IgG) his serum IgG had decreased to 56 m g / 100 ml and his IgM had decreased to 7 mg/100 ml. After four doses of transfer factor, 168 days post-IgG therapy, his serum IgG rose to 110 mg/ 100 ml and his IgM decreased to undetectable levels. After 270 days his IgG was 130 mg/100 ml with undetectable IgM. Throughout the course his salivary and serum IgA have remained undetectable. N o change post-transfer factor therapy was noted in his Schick test which remained positive.
DISCUSSION
Although agammaglobulinemia has been considered a stem cell deficiency involving B lymphocytes, a number of investigators have questioned this hypothesis in recent years (16, 19, 21) . It has been shown that the peripheral blood lymphocytes of some patients with congenital aggamaglobulinemia have the capacity to synthesize normal amounts of y-globulin when stimulated in short term culture (8, 25) . Similarly, long term lymphoid cell lines, derived from patients with hypogammaglobulinemia have the capacity to synthesize immunoglobulins in vitro (25) . These lines appear to be B cells as determined by E A C rosetting, immunofluorescence, and immunoglobulin synthesis (I I). As has been described for others (7) . our patient with agammaglobulinemia and a history of recurrent infections was found to have small numbers of circulating B cells with surface immunoglobulins of the a, y, and heavy chain classes. It was further demonstrated by radioimmunoelectrophoresis that his lymphocytes, when stimulated in vitro with pokeweed mitogen, synthesized heavy chain classes of immunoglobulins with a restricted population of p heavy chains. Low levels of serum IgM were present in this patient throughout his course, despite the extremely Fig. 1 . Radioimmunoelectrophoretic study of the in vitro synthesis of immunoglobulins by the pokeweed mitogen-stimulated peripheral lymphocytes of palient JF. A: fast green-stained immunoelectrophoretic patterns for comparative study. B: autoradiograph of the coprecipitated, labeled heavy chains synthesized in vitro. Wells @) contain cell lysates from the patient. Trough I was filled with rabbit anti-human polyvalent antiserum against human a , y, and p heavy chain classes of immunoglobulin. Trough 2 was filled with rabbit anti-human antiserum specific for the a chain of human immunoglobulin. Trough 3 was filled with rabbit anti-human antiserum specific for the fi chain of human immunoglobulin. Trough 4 was filled with rabbit antihuman antiserum specific for the y chain of human immunoglobulin. Newly synthesized molecules of y chain with a broad ratlge of mobility can be seen. a and p chains with restricted mobility are also present. (21) have demonstrated that the lymphocytes of patients with infantile x-linked agammaglobulinemia have a diminished response to P H A . They postulate that these patients might be deficient in a restricted population of T cells which may be necessary for the full maturation of B cell function. In a rapidly expanding series of elegant experiments in many laboratories (13) , it has been shown for the mouse that T cells are necessary for appropriate immunoglobulin production and antibody synthesis by B cells. T cell interaction appears to be instrumental in the switch from IgM to
IgG synthesis. Subpopulations of T cells may lead to B cell supression as well as facilitation (10) .
By gross testing, the T cell responses of our patient appeared to be intact with normal numbers of circulating T cells, cutaneous reactivity to a variety of antigens, and in vitro P H A responsiveness. The presence of circulating IgM, however, suggested that the patient's B cells can function but that faulty T-B cell interactions might exist. Since 1954, Lawrence has reported the transfer of cell-mediated immunity in man with an extract of peripheral leukocytes from immune individuals. The activity, presumably derived from T lymphocytes, is associated with a low molecular weight material, < 10,000 (current estimates 4,000-6,000), which can be separated from immunoglobulins and large molecular weight informational proteins by dialysis. Because it is free of HL-A antigens and appears to have little or no immunogenicity, dialyzable transfer factor is now under intensive study as a therapeutic agent in a variety of immune and neoplastic disorders (23, 26) . Transfer factor has been used in the therapy of the Wiskott-Aidrich syndrome, chronic mucocutaneous candidiasis, Swiss-type agammaglobulinemia, malignancies, lepromatous leprosy, and disseminated vaccinia with varying degrees of success. Although it seems to be most useful in T cell disorders, transfer factor similarly has been shown to transfer enduring delayed sensitivity to a variety of antigens in patients with congenital agammaglobulinemia (2) . N o apparent alteration in B cell functions, however, has been noted in these patients after therapy with transfer factor. The direct influence of transfer factor on T-B cell interaction has not been reported.
It was clear that administration of exogenous y-globulin by intramuscular injection as frequently as every 2 weeks did not significantly increase the serum IgG levels in our patient nor did it decrease his pyogenic infections. It is possible that he had an unusual catabolism of these proteins (not investigated) and/or that the exogenous y-globulin he was given suppressed his endogenous synthesis by potentially functional B cells. Within 50 days of the discontinuation of y-globulin therapy, his serum IgG fell to 70 mg/ 100 ml. Although it is possible that he may have subsequently begun to produce endogenous IgG, we attempted to augment his responses at the time with transfer factor. After treating the patient with three doses of transfer factor at biweekly intervals, followed by a fourth dose 1 month later, his IgM level became undetectable with an increase in his IgG level from a low of 50 mg/100 ml to 130 mg/100 ml. This is comparable with the levels achieved with exogenous IgG therapy. This level has remained stable for the past 12 months with trimonthly transfer factor injections. Of particular interest, despite no appreciable difference in IgG level and the apparent loss of circulating IgM, this regimen, which has included stopping exogenous y-globulin and the administration of transfer factor, has been accompanied by an overall improvement in the patient's clinical state. Whereas before transfer factor with biweekly y-globulin doses he had at least 1 infection/month with hospitalizations every 2-3 months, with the new therapeutic regimen he has been virtually free of infections for the past 12 months. One presumed viral illness occurred during the 7th month of transfer factor therapy. The patient had an uneventful course and recovered without sequelae. This prolonged amelioration in the clinical state in our experience is unlikely to reflect the natural variability of his immunodeficiency disorder.
Lim et al. (18) have suggested that transfer factor may nonspecifically augment the immune responses of the recipient. Our studies in this patient with agammaglobulinemia have shown that transfer factor therapy may affect immunoglobulin synthesis as has been suggested by Gelfand et a/. (9), but we are hard put to provide specific immunologic proof of this interaction. We have noted the disappearance of the serum IgM of our patient during transfer factor therapy with resulting increases in his serum IgG levels. Although it is possible that his alteration in serum immunoglobulins results from removal of the suppression by exogenous y-globulin of his endogenous synthesis, we suspect that the switch from IgM to IgG synthesis may have been accomplished by a nonspecific facilitation by transfer factor of T-B cell interaction in our patient. Unfortunately, no specific changes in antibody response (particularly Schick reactivity) were detected to confirm that a switch in antibody production had occurred as well. Since the radioimmunoelectrophoretic patterns of heavy chains newly synthesized by his stimulated lymphocytes demonstrated wide heterogeneity, it is unlikely that this additional approach will offer any immunologic confirmation of the production of new species of IgG in our patient. W e await further detailed reports of the effects of transfer factor in the therapy of patients with B cell dysfunction.
SUMMARY
Transfer factor therapy has been shown to alter the clinical course of a patient with agammaglobulinemia. Because of the concurrent discontinuation of exogenous y-globulin administration, it is difficult to attribute changes to a particular aspect of therapy. Further reports of the effects of transfer factor in the therapy of patients with B cell disorders are needed.
